Please login to the form below

Not currently logged in
Email:
Password:

betrixaban

This page shows the latest betrixaban news and features for those working in and with pharma, biotech and healthcare.

CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer

CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer

It also turned down two previously-rejected medicines – Portola’s factor Xa inhibitor anticoagulant Dexxience (betrixaban) and Radius International’s osteoporosis candidate Eladynos (abaloparatide) – for the second time after a

Latest news

  • CHMP backs first-line use for AZ’s Tagrisso in lung cancer CHMP backs first-line use for AZ’s Tagrisso in lung cancer

    The three drugs in question are Portola’s anticagulant Dexxience (betrixaban), Radius’osteoporosis candidate Eladynos (abaloparatide) and AB Science’s Alsitek (masitinib), filed for neurodegenerative disease amyotrophic lateral sclerosis (ALS).

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    There was bad news for three other companies, with the CHMP issuing negative opinions for Portola’s Dexxience (betrixaban) for the prevention of venous thromboembolism, Radius International’s osteoporosis candidate Eladynos

  • Bad news for Portola as CHMP considers Factor Xa drugs Bad news for Portola as CHMP considers Factor Xa drugs

    Bad news for Portola as CHMP considers Factor Xa drugs. The committee are ‘unlikely’to adopt a positive opinion for betrixaban. ... for betrixaban, its oral, once-daily Factor Xa inhibitor, as well as antidote drug andexanet alfa.

  • Archive listing

    The committee are ‘unlikely’to adopt a positive opinion for betrixaban. .

  • Merck collaborate over betrixaban

    In return for an exclusive worldwide license to betrixaban, Merck will pay Portola an initial fee of $50m. ... for additional royalties and to co-promote betrixaban with Merck in the US.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Betrixaban. Betrixaban (Portola Pharmaceuticals) is a long-acting oral factor Xa inhibitor that entered phase III trial development for VTE prevention in medically ill patients in March 2012. ... Promising phase II results of betrixaban for VTE

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics